Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ARQT Stock Forecast 2026-2027
$24.53
Current Price
$3.04B
Market Cap
Buy 7
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ARQT Price Targets
+46.8%
To High Target of $36.00
+42.7%
To Median Target of $35.00
+34.5%
To Low Target of $33.00
ARQT Price Momentum
+1.7%
1 Week Change
+10.4%
1 Month Change
+88.5%
1 Year Change
-15.5%
Year-to-Date Change
-22.8%
From 52W High of $31.77
+97.5%
From 52W Low of $12.42
📊 TOP ANALYST CALLS
Did ARQT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Arcutis is one of their latest high-conviction picks.
Latest ARQT Stock Price Targets & Analyst Predictions
Based on our analysis of 17 Wall Street analysts, ARQT has a bullish consensus with a median price target of $35.00 (ranging from $33.00 to $36.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $24.53, the median forecast implies a 42.7% upside. This outlook is supported by 7 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Serge Belanger at Needham, projecting a 46.8% upside. Conversely, the most conservative target is provided by Jonathan Block at Goldman Sachs, suggesting a 34.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ARQT Analyst Ratings
7
Buy
1
Hold
0
Sell
ARQT Price Target Range
Low
$33.00
Average
$35.00
High
$36.00
Current: $24.53
Latest ARQT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ARQT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 2, 2026 | Mizuho | Uy Ear | Outperform | Maintains | $35.00 |
| Feb 27, 2026 | Guggenheim | Seamus Fernandez | Buy | Maintains | $35.00 |
| Feb 26, 2026 | Needham | Serge Belanger | Buy | Maintains | $36.00 |
| Feb 26, 2026 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $34.00 |
| Feb 26, 2026 | TD Cowen | Tyler Van Buren | Buy | Maintains | $35.00 |
| Jan 26, 2026 | Needham | Serge Belanger | Buy | Maintains | $31.00 |
| Nov 28, 2025 | Mizuho | Uy Ear | Outperform | Maintains | $37.00 |
| Oct 30, 2025 | Goldman Sachs | Richard Law | Neutral | Maintains | $29.00 |
| Oct 28, 2025 | Needham | Serge Belanger | Buy | Maintains | $30.00 |
| Aug 7, 2025 | Needham | Serge Belanger | Buy | Maintains | $22.00 |
| Jul 25, 2025 | Goldman Sachs | Richard Law | Neutral | Initiates | $18.00 |
| May 23, 2025 | Needham | Serge Belanger | Buy | Reiterates | $20.00 |
| Apr 9, 2025 | Needham | Serge Belanger | Buy | Reiterates | $20.00 |
| Apr 3, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $19.00 |
| Apr 3, 2025 | Needham | Serge Belanger | Buy | Reiterates | $20.00 |
| Apr 3, 2025 | Guggenheim | Seamus Fernandez | Buy | Reiterates | $N/A |
| Mar 11, 2025 | Jefferies | Kambiz Yazdi | Buy | Maintains | $19.00 |
| Feb 27, 2025 | Goldman Sachs | Jonathan Block | Neutral | Maintains | $15.00 |
| Feb 26, 2025 | Mizuho | Uy Ear | Outperform | Maintains | $21.00 |
| Feb 26, 2025 | Needham | Serge Belanger | Buy | Reiterates | $20.00 |
Arcutis Biotherapeutics Inc. (ARQT) Competitors
The following stocks are similar to Arcutis based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Arcutis Biotherapeutics Inc. (ARQT) Financial Data
Arcutis Biotherapeutics Inc. has a market capitalization of $3.04B with a P/E ratio of -188.8x. The company generates $376.07M in trailing twelve-month revenue with a -4.3% profit margin.
Revenue growth is +81.5% quarter-over-quarter, while maintaining an operating margin of +14.2% and return on equity of -9.3%.
Valuation Metrics
Market Cap
$3.04B
Enterprise Value
$2.94B
P/E Ratio
-188.8x
PEG Ratio
0.7x
Price/Sales
8.1x
Growth & Margins
Revenue Growth (YoY)
+81.5%
Gross Margin
+91.0%
Operating Margin
+14.2%
Net Margin
-4.3%
EPS Growth
+81.5%
Financial Health
Cash/Price Ratio
+7.3%
Current Ratio
3.2x
Debt/Equity
60.4x
ROE
-9.3%
ROA
-2.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Arcutis Biotherapeutics Inc. (ARQT) Business Model
About Arcutis Biotherapeutics Inc.
What They Do
Develops treatments for immune-mediated skin diseases.
Business Model
The company commercializes innovative topical therapies, generating revenue primarily through its flagship product, ZORYVE, which is a steroid-free cream and foam for treating various skin conditions. They also advance a pipeline of therapies targeting additional dermatological conditions, potentially creating future revenue streams as new products are developed and approved.
Additional Information
Arcutis is focused on expanding its regulatory approvals and clinical advancements, with ongoing trials for new applications of ZORYVE and other products like ARQ-234. Their approach aims to meet unmet needs in chronic inflammatory skin diseases, enhancing patient outcomes through user-friendly treatments.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
354
CEO
Mr. Todd Franklin Watanabe M.A.
Country
United States
IPO Year
2020
Website
www.arcutis.comArcutis Biotherapeutics Inc. (ARQT) Latest News & Analysis
Latest News
Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
5 days ago
Quick Summary
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) will report its Q1 2026 financial results and business update on May 6, 2026, after market close.
Why It Matters
Arcutis Biotherapeutics’ upcoming financial results and business update may impact its stock price and investor sentiment, reflecting its performance and strategic direction in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know
12 days ago
Quick Summary
On April 1, 2026, an Arcutis Biotherapeutics director sold 10,000 shares for $239,000, representing 20.10% of their holdings.
Why It Matters
A director's significant share sale may signal a lack of confidence in the company's future, potentially influencing stock price and investor sentiment negatively.
Source: The Motley Fool
Market Sentiment:
Negative
Quick Summary
Arcutis will present at the 25th Annual Needham Virtual Healthcare Conference from April 13-16, 2026.
Why It Matters
Arcutis' participation in a major healthcare conference may signal upcoming developments or announcements, influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Arcutis Biotherapeutics announced positive Phase 2 trial results for ZORYVE® cream, showing rapid improvement in atopic dermatitis symptoms in infants. Safety profile aligns with prior data.
Why It Matters
Positive trial results for ZORYVE cream enhance Arcutis Biotherapeutics' growth potential in dermatology, possibly boosting stock performance and attracting investment interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Arcutis Biotherapeutics (Nasdaq: ARQT) will present new clinical data and updates on its ZORYVE® portfolio at the AAD Annual Meeting from March 27-31, 2026, in Denver.
Why It Matters
New clinical data presentation by Arcutis Biotherapeutics could influence stock performance, signaling potential growth in their product pipeline and impacting investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Arcutis Biotherapeutics announced positive Phase 3 results for ZORYVE cream in children aged 2-5 with atopic dermatitis, showing safety and sustained efficacy over 56 weeks.
Why It Matters
Positive clinical results for ZORYVE cream enhance Arcutis Biotherapeutics' market position, potentially increasing revenue from pediatric treatments and attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ARQT Stock
What is Arcutis Biotherapeutics Inc.'s (ARQT) stock forecast for 2026?
Based on our analysis of 17 Wall Street analysts, Arcutis Biotherapeutics Inc. (ARQT) has a median price target of $35.00. The highest price target is $36.00 and the lowest is $33.00.
Is ARQT stock a good investment in 2026?
According to current analyst ratings, ARQT has 7 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $24.53. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ARQT stock?
Wall Street analysts predict ARQT stock could reach $35.00 in the next 12 months. This represents a 42.7% increase from the current price of $24.53. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Arcutis Biotherapeutics Inc.'s business model?
The company commercializes innovative topical therapies, generating revenue primarily through its flagship product, ZORYVE, which is a steroid-free cream and foam for treating various skin conditions. They also advance a pipeline of therapies targeting additional dermatological conditions, potentially creating future revenue streams as new products are developed and approved.
What is the highest forecasted price for ARQT Arcutis Biotherapeutics Inc.?
The highest price target for ARQT is $36.00 from Serge Belanger at Needham, which represents a 46.8% increase from the current price of $24.53.
What is the lowest forecasted price for ARQT Arcutis Biotherapeutics Inc.?
The lowest price target for ARQT is $33.00 from Jonathan Block at Goldman Sachs, which represents a 34.5% increase from the current price of $24.53.
What is the overall ARQT consensus from analysts for Arcutis Biotherapeutics Inc.?
The overall analyst consensus for ARQT is bullish. Out of 17 Wall Street analysts, 7 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $35.00.
How accurate are ARQT stock price projections?
Stock price projections, including those for Arcutis Biotherapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 20, 2026 10:02 AM UTC